AU749921B2 - A soluble vaccinia virus protein that binds chemokines - Google Patents

A soluble vaccinia virus protein that binds chemokines Download PDF

Info

Publication number
AU749921B2
AU749921B2 AU63020/98A AU6302098A AU749921B2 AU 749921 B2 AU749921 B2 AU 749921B2 AU 63020/98 A AU63020/98 A AU 63020/98A AU 6302098 A AU6302098 A AU 6302098A AU 749921 B2 AU749921 B2 AU 749921B2
Authority
AU
Australia
Prior art keywords
protein
chemokine
amino acid
fragment
chemokines
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU63020/98A
Other languages
English (en)
Other versions
AU6302098A (en
Inventor
Aylwin Ng
Geoffrey Smith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oxford University Innovation Ltd
Original Assignee
Oxford University Innovation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9703592.7A external-priority patent/GB9703592D0/en
Priority claimed from GBGB9800113.4A external-priority patent/GB9800113D0/en
Application filed by Oxford University Innovation Ltd filed Critical Oxford University Innovation Ltd
Publication of AU6302098A publication Critical patent/AU6302098A/en
Application granted granted Critical
Publication of AU749921B2 publication Critical patent/AU749921B2/en
Priority to AU2002301315A priority Critical patent/AU2002301315B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU63020/98A 1997-02-21 1998-02-23 A soluble vaccinia virus protein that binds chemokines Ceased AU749921B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002301315A AU2002301315B2 (en) 1997-02-21 2002-10-03 A soluble vaccinia virus protein that binds chemokines

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB9703592.7A GB9703592D0 (en) 1997-02-21 1997-02-21 Poxvirus chemokine-binding protein
GB9703592 1997-02-21
GB9800113 1998-01-05
GBGB9800113.4A GB9800113D0 (en) 1998-01-05 1998-01-05 A soluble vaccinia virus protein that binds chemokines
PCT/GB1998/000569 WO1998037217A1 (en) 1997-02-21 1998-02-23 A soluble vaccinia virus protein that binds chemokines

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2002301315A Division AU2002301315B2 (en) 1997-02-21 2002-10-03 A soluble vaccinia virus protein that binds chemokines

Publications (2)

Publication Number Publication Date
AU6302098A AU6302098A (en) 1998-09-09
AU749921B2 true AU749921B2 (en) 2002-07-04

Family

ID=26311039

Family Applications (1)

Application Number Title Priority Date Filing Date
AU63020/98A Ceased AU749921B2 (en) 1997-02-21 1998-02-23 A soluble vaccinia virus protein that binds chemokines

Country Status (7)

Country Link
US (3) US6355252B1 (enExample)
EP (2) EP0985046B1 (enExample)
JP (1) JP4191255B2 (enExample)
AT (1) ATE323170T1 (enExample)
AU (1) AU749921B2 (enExample)
DE (1) DE69834179T2 (enExample)
WO (1) WO1998037217A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69834179T2 (de) * 1997-02-21 2007-02-01 Oxxon Therapeutics Ltd. Rekombinantes pockenvirus das das lösliche chemokine-bindende protein kodierende gen a41l nicht exprimieren kann.
GB9711957D0 (en) * 1997-06-09 1997-08-06 Isis Innovation Methods and reagents for vaccination
US20040241163A1 (en) * 2001-04-05 2004-12-02 Thomas Shenk Compositions and methods for treating inflammation and related conditions
AU2002346056A1 (en) * 2001-07-12 2003-01-29 Immunex Corporation Viral proteins capable of binding lar
GB0118532D0 (en) * 2001-07-30 2001-09-19 Isis Innovation Materials and methods relating to improved vaccination strategies
MXPA04002575A (es) * 2001-09-20 2004-06-18 Schering Corp Quimiocinas como adyuventes de respuesta inmune.
AU2003259117A1 (en) * 2002-07-10 2004-01-23 The Regents Of The University Of California Antimicrobial activity of interferon-inducible elr chemokines
AU2003258168B2 (en) * 2002-08-12 2009-10-29 Sillajen Biotherapeutics, Inc. Methods and compositions concerning poxviruses and cancer
WO2005017208A1 (en) * 2003-07-31 2005-02-24 George Mason Intellectual Properties, Inc. Compositions and methods for treating or preventing hiv infection
US20050175627A1 (en) * 2003-09-24 2005-08-11 Oxxon Therapeutics Ltd. HIV pharmaccines
US20070160571A1 (en) * 2006-01-11 2007-07-12 Mitchell Krathwohl Composition and method for inducing protective vaccine response
WO2006076383A2 (en) * 2005-01-11 2006-07-20 Rosetta Stone Labs, Llc Composition and method for inducing a protective vaccine response
US8980246B2 (en) 2005-09-07 2015-03-17 Sillajen Biotherapeutics, Inc. Oncolytic vaccinia virus cancer therapy
EP1933857A2 (en) * 2005-09-07 2008-06-25 Jennerex Biotherapeutics ULC Systemic treatment of metastatic and/or systemically-disseminated cancers using gm-csf-expressing poxviruses
EP1928916A2 (en) * 2005-09-29 2008-06-11 Viral Logic Systems Technology Corp. Immunomodulatory compositions and uses therefor
ES2354954T3 (es) 2006-03-22 2011-03-21 Viral Logic Systems Technology Corp. Métodos para identificar dianas polipeptídicas.
US20110044945A1 (en) * 2007-02-08 2011-02-24 Rappaport Family Institute For Research In The Medical Sciences Agents for the treatment of multiple sclerosis and methods of using same
KR20080084528A (ko) * 2007-03-15 2008-09-19 제네렉스 바이오테라퓨틱스 인크. 종양살상형 백시니아 바이러스 암 치료
WO2008149354A2 (en) 2007-06-04 2008-12-11 Rappaport Family Institute For Research In The Medical Sciences Agents for the treatment of inflammatory diseases and methods of using same
WO2009082594A2 (en) 2007-11-26 2009-07-02 Fox Chase Cancer Center Secreted/cell bound poxvirus proteins and methods of use thereof as vaccines and anti-viral agents
WO2010103517A1 (en) 2009-03-12 2010-09-16 Rappaport Family Institute For Research In The Medical Sciences Soluble compositions for the treatment of cxcr3-ligand associated diseases
EP2477499B1 (en) 2009-09-14 2018-04-11 SillaJen Biotherapeutics, Inc. Oncolytic vaccinia virus combination cancer therapy
CN103429258B (zh) 2011-01-04 2016-03-09 新罗杰公司 通过施用溶瘤痘苗病毒生成针对肿瘤抗原的抗体和生成肿瘤特异性补体依赖性细胞毒性

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69628838T2 (de) 1995-04-19 2004-05-06 The John P. Robarts Research Institute, London Chemokin bindendes protein und verfahren zu seiner verwendung
US6140064A (en) 1996-09-10 2000-10-31 Theodor-Kocher Institute Method of detecting or identifying ligands, inhibitors or promoters of CXC chemokine receptor 3
DE69834179T2 (de) * 1997-02-21 2007-02-01 Oxxon Therapeutics Ltd. Rekombinantes pockenvirus das das lösliche chemokine-bindende protein kodierende gen a41l nicht exprimieren kann.
WO1998036766A1 (en) * 1997-02-21 1998-08-27 Isis Innovation Limited Anti-hiv protein
JP2001168323A (ja) * 1999-12-06 2001-06-22 Mitsubishi Electric Corp 半導体装置の製造方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
J. GZN VIROL, 1990, 71 (PT 9), PAGES 2013-2021 *
VIROLOGY, VOL 180, P 633-647, (1991) *

Also Published As

Publication number Publication date
EP0985046B1 (en) 2006-04-12
JP2001513629A (ja) 2001-09-04
US20020071849A1 (en) 2002-06-13
US7384643B2 (en) 2008-06-10
DE69834179T2 (de) 2007-02-01
EP0985046A1 (en) 2000-03-15
US6355252B1 (en) 2002-03-12
DE69834179D1 (de) 2006-05-24
US20040142002A1 (en) 2004-07-22
JP4191255B2 (ja) 2008-12-03
EP1405916A1 (en) 2004-04-07
WO1998037217A1 (en) 1998-08-27
ATE323170T1 (de) 2006-04-15
AU6302098A (en) 1998-09-09

Similar Documents

Publication Publication Date Title
AU749921B2 (en) A soluble vaccinia virus protein that binds chemokines
Alcami et al. A soluble receptor for interleukin-1β encoded by vaccinia virus: a novel mechanism of virus modulation of the host response to infection
Upton et al. Myxoma virus expresses a secreted protein with homology to the tumor necrosis factor receptor gene family that contributes to viral virulence
Symons et al. Vaccinia virus encodes a soluble type I interferon receptor of novel structure and broad species specificity
Blanchard et al. Modified vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins: implications for use as a human vaccine.
Smith et al. Vaccinia virus immune evasion: mechanisms, virulence and immunogenicity
Lalani et al. Functional comparisons among members of the poxvirus T1/35kDa family of soluble CC-chemokine inhibitor glycoproteins
KR100196204B1 (ko) 폭스비루스 성분의 조합에 기초한 파라뮤니티 유발인자, 그의 제조방법 및 그의 약제에의 이용
CA2218499C (en) Chemokine binding protein and methods of use therefor
EP0555291A1 (en) Vaccinia vectors, vaccinia genes and expression products thereof
US5476781A (en) Entomopoxvirus spheroidin gene sequences
EP0397560A2 (en) Spheroidin DNA isolate and recombinant entomopoxvirus expression vectors
Chen et al. Analysis of host response modifier ORFs of ectromelia virus, the causative agent of mousepox
JP2007082551A (ja) 組換えポックスウイルス−カリシウイルス［ウサギ出血疾患ウイルス（ｒｈｄｖ）］組成物および使用
US5721352A (en) Entomopoxvirus expression system
AU2002301315B2 (en) A soluble vaccinia virus protein that binds chemokines
US6933145B1 (en) Materials and methods for delivery and expression of heterologous DNA in vertebrate cells
WO1993018153A1 (en) Vaccinia virus b15r used in interleukin b1-involving condition
IE920515A1 (en) Novel Entomopoxvirus Expression System
EP1307572A2 (en) Materials and methods for delivery and expression of heterologous dna in vertebrate cells
WO1998036766A1 (en) Anti-hiv protein
RU2588388C1 (ru) Рекомбинантный штамм л-ивп 1421abjcn вируса осповакцины с нарушенными генами вирулентности a56r, b8r, j2r, c3l, n1l для получения живой культуральной аттенуированной вакцины против натуральной оспы и других ортопоксвирусов, патогенных для человека
CN100393872C (zh) 复制缺陷型天坛株痘苗病毒
Ness Investigation of the rabbitpox virus 35kDa protein: Its interactions with chemokines and its role in poxvirus pathogenesis
Aziz Enhancing the safety and efficacy of recombinant vaccinia virus vaccines

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired